2023 Biochemical Assays Clinical Research Research 
Drug Target Review
JULY 12, 2023
Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). We are pleased that to date our lead product candidate has aligned DCI profiles as expected.
Drug Discovery World
APRIL 11, 2024
The Program Committee Chairs commented: “It has been an educational, enlightening, and inspiring week of captivating cancer science and research. Research highlights Blacksmith Medicines announced preclinical data on its oncology programme targeting flap endonuclease 1 (FEN1). And thanks to the city of San Diego for its hospitality.”
Expert insights. Personalized for you.
98 
Let's personalize your content